Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

Impact · against what's priced in

The Phase III interim data for povetacicept significantly reduces the binary risk associated with the November 30 FDA action date, providing a concrete catalyst for the renal pipeline. While the $10 billion franchise target gives a revenue ceiling, the immediate impact is a shift in the probability of success for the first renal product, which the market has not yet fully priced in.

VRTX+0.40

Challenges what's priced in

The price assumes